The first inter partes review petitions backed by Kyle Bass’ Hayman Capital have been rejected by the Patent Trial and Appeal Board.
Bass’ strategy of targeting pharmaceutical company patents while simultaneously shorting their stock has been attacked by the industry as an abuse of the IPR process. But on Monday the PTAB steered clear of the controversy, relying instead on technical shortcomings in the petition to decline instituting proceedings.
This content has been archived. It is available through our partners, LexisNexis® and Bloomberg Law.
To view this content, please continue to their sites.
Not a Lexis Subscriber?
Subscribe Now
Not a Bloomberg Law Subscriber?
Subscribe Now
LexisNexis® and Bloomberg Law are third party online distributors of the broad collection of current and archived versions of ALM's legal news publications. LexisNexis® and Bloomberg Law customers are able to access and use ALM's content, including content from the National Law Journal, The American Lawyer, Legaltech News, The New York Law Journal, and Corporate Counsel, as well as other sources of legal information.
For questions call 1-877-256-2472 or contact us at [email protected]
